Search results for: Margherita Neri
Filter search results
Rare Disease Day 2024: Why Do We Care About Rare?
29 February 2024
…Health Care. 2021;37(S1):19-19. doi:10.1017/S0266462321001124 Berdud M, Drummond M, Towse A. Establishing a reasonable price for an orphan drug. Cost Eff Resour Alloc. 2020;18(1):31. doi:10.1186/s12962-020-00223-x Cole A, Neri M, Cookson G….
Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology
3 July 2018
…Technology Assessments in Oncology. OHE Consulting Report, London: Office of Health Economics. RePEc Related Research Lorgelly, P.K. and Neri, M. 2018. Survivorship Burden for Individuals, Households and Society:…
Incentives, Competition, and Pharmaceutical Innovation in Europe: The Case of Direct Acting Antivirals for Hepatitis C
26 July 2018
…the healthcare system and political factors, which can have an effect. Download the full report here. Citation Berdud, M., Garau, M., Neri, M., O’Neill, P., Sampson, C….
Recommendations for Making Outcome-based Payments a Reality in the NHS: An Application to Cancer Drugs
21 February 2019
…A., Lorgelly, P., and Sullivan, R., 2018. Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals. OHE Research Paper 18/04. RePEc. Lorgelly, P.K. and Neri, M., 2018. Survivorship…
OHE Launches Discussion Paper and Consultation Exercise on Indication-based Pricing
10 May 2019
…Pricing in the US and Five Major European Countries . Consulting Report, Office of Health Economics. Neri, M., Towse, A., and Garau, M., 2018. Multi-Indication Pricing (MIP): Practical Solutions and…
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
…of Risperidone. OHE Research Paper 19/xx, London: Office of Health Economics. Available at: https://www.ohe.org/publications/case-risperidone-assessing-life-cycle-value-second-generation-antipsychotics-sweden-and Related research Berdud, M., Garau, M., Neri, M., O’Neill, P., Sampson, C. and Towse, A….
HTA and Payment Mechanisms for New Drugs to Tackle AMR
23 September 2019
…when more expensive ones may be appropriate. ‘Volume-delinked’ payments may instead represent a longer-term solution because these schemes encourage better adherence to stewardship. Neri, M., Hampson, G., Henshall, C….
Making Outcome-based Payment a Reality in the NHS: Moving to the Next Phase
3 October 2019
…Cole, A., Towse, A., Lorgelly, P., and Sullivan, R., 2018. Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals. OHE Research Paper 18/04. RePEc. Lorgelly, P.K. and Neri,…
OHE Presents at Global AMR R&D Hub Board of Members Meeting in Paris
18 December 2019
…available here. Neri, M., Hampson, G., Henshall, C. and Towse, A., 2019. HTA and payment mechanisms for new drugs to tackle AMR. OHE Research Paper, London: Office of Health…